Open Government Portal
MaintenanceWe are performing scheduled maintenance from 8:00am to 12:00pm, Monday, December 4th, Eastern time.
Anyone can find out if a submission has been accepted for review by Health Canada by searching the submissions under review list. We publish Regulatory Decision Summaries (RDS). These summaries explain the purpose of the submission and the reason(s) for Health Canada’s decision on certain health products seeking market authorization. You can access RDSs through the Drug and Health Product Register.
Canada’s health care system is complex and involves the participation of multiple stakeholders, who all have distinct roles in the planning and delivery of healthcare services. Health Canada’s decision-making role in approving a drug for marketing is distinct from the roles of those who make decisions about price-setting and public drug plan reimbursements.
The file contains record for every offender serving a sentence of two years or more under Correctional Services of Canada (CSC) jurisdiction. The data were extracted from the Offender Management System (OMS) and reflects the status and attributes of offenders as of the year end. This file contains links to all of the offender profiles since 2012 and will get updated annually.
Special access programs.
To develop options for the registration and disclosure of clinical trial information of health products in Canada, Health Canada began consulting with Canadians in 2005.
Drug and medical device approval overview
The purpose of this policy is to ensure timely access to drug/medical device combination products by establishing a single window approach and more efficient submission processing system, while ensuring that combination products marketed in Canada are safe, effective, and of high quality.
Briefing Package for the hearing before the Standing Committee on Public Accounts on 2023 Report 2, Connectivity in Rural and Remote Areas of the Office of the Auditor General of Canada
This guidance is intended to assist sponsors in the collection and analysis of data for Steroid Nasal products for use in the treatment of allergic rhinitis, in order to meet the safety and effectiveness requirements under Part C, Division 8 of the Food and Drug Regulations.
Depending on its ingredients, a dental plaque-disclosing product can be regulated as a drug under the F&DA either as a pharmaceutical drug subject to the Food and Drug Regulations and requires a Drug Identification Number (DIN), or as a natural health product subject to the Natural Health Products Regulations and require a Natural Product Number (NPN).